Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1998-03-10
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 530324, 530325, 530326, 424 11, 436504, A61K 3800, A61K 3804, C07K 500, C07K 700
Patent
active
057261539
ABSTRACT:
Vascular disease including asymptomatic atherosclerosis can be diagnosed by administering a synthetic peptide or peptide analog having an affinity for, and propensity to accumulate at, a site of vascular injury to a patient, and then detecting the location of the peptide or peptide analog within the patient's vascular system. The synthetic peptide or peptide analog may include an amino acid sequence sufficiently duplicative of the amino acid sequence of a region of either the apolipoprotein B, apolipoprotein A-I, or elastin proteins such that the peptide or peptide analog accumulates at a site of vascular injury.
REFERENCES:
patent: 4116776 (1978-09-01), Dalbow et al.
patent: 4359453 (1982-11-01), Gordon
patent: 4577636 (1986-03-01), Spears
patent: 4643988 (1987-02-01), Segrest et al.
patent: 4647445 (1987-03-01), Lees
patent: 4660563 (1987-04-01), Lees
patent: 4668503 (1987-05-01), Hnatowich
Cardin et., 1982, Biochemistry, 21:4503, Sulfhdryl Chemistry and Solubility Properties of Human Plasma Apolipoprotein B.
Lees and Myers, 1982, Advances in Internal Medicine, 27:475, Noninvasive Diagnosis of Arterial Disease.
Camejo, 1982, Advances in Lipid Research, 19:1, The Interaction of Lipids and Lipoproteins with the Inter-Cellular Matrix of Arterial Tissue: its Possible Role in Atherogenesis.
Camejo et al., 1983, Artherosclerosis 49:241, Partial Structure of the Active Moiety of a Lipoprotein Complexing Proteglycan from Human Aorta.
Lees and Lees, 1983, Proc. Natl. Acad. Sci. USA, 80:5098, Low Density Lipoprotein Degradation by Mononuclear Cells from Normal and Dyslipoproteinemic Subjects.
Roberts et al., 1983, Journal of Lipid Research, 24:1160, Selective Accumulation of Low Density Lipoproteins in Damaged Arterial Wall.
Lees et al., 1983, J. Nucl. Med. 24:154, External Imaging of Human Atherosclerosis.
Hnatowich et al., 1983, Science 220:613, Radioactive Labeling of Antibody: A Simple and Efficient Method.
Mateu et al., 1984, Biochemica et Biophysica Acta, 795:525, The Structural Stability of Low-Density Lipoprotein. A Kinetic X-ray Scattering Study of its Interaction with Arterial Proteoglycans.
Meares et al., 1984, Analytic Biochemistry, 142:68, Conjugation of Antibodies With Bifunctional Chelating Agents: Isothiocyanate and Bromoacetamide Reagents, Methods of Analysis, and Subsequent Addition . . . .
Stewart et al., 1984, Solid Phase Peptide Synthesis. Laboratory Techniques in Peptide Synthesis, pp. 53-63.
Carlsson et al., 1985, Nucleic Acids Research, 13:8813, Molecular Cloning of Human Apolipoprotein B CDNA.
Forgez et al., 1986, Biochemical and Biophysical Research Communications, 140:250, Identification of Surface Exposed Segments of Apolipoprotein B-100 in the LDL Particle.
Knott et al., 1986, Nature, 323-734, Complete Protein Sequence and Identification of Structural Domains of Human Apolipoprotein B.
Law et al., 1986, Proc. Natl. Acad. Sci. USA, 83:8142, Human Liver Apolipoprotein B-100 CDNA: Complete Nucleic Acid and Derived Amino Acid Sequence.
Wegrowski et al., 1986, Biochem. J., 235:823, Proteoglycans From Pig Aorta.
Yang et al., 1986, Nature, 323:738, Sequence, Structure, Receptor-Binding Domains and Internal Repeats of Human Apolipoprotein B-100.
Fischman et al., 1987, Arteriosclerosis, 7:361, Accumulation of Native and Methylated Low Density Lipoproteins by Healing Rabbit Arterial Wall.
Lusis et al., 1985, Proc. Natl. Acad. Sci. USA, 82:4597, Cloning and Expression of Apolipoprotein B, The Major Protein of Low and Very Low Density Lipoproteins.
Hollander et al., 1979, Arthrosclerosis, 34:391, Soluble Proteins in the Human Atherosclerotic Plaque.
Blood et al., 1988, J. Cell Biology, 107:1987, Identification of a Tumor Cell Receptor for VGVAPG, an Elastin-Derived Chemotactic Peptide.
Schultz et al., 1979, Principles of Protein Structure, published by Springer-Verlag (N.Y.).
Van Vunakis et al., 1980, Methods in Enzymology, 70:201, Immunochemical Techniques Part A.
Shih et al., 1990, Proc. Natl. Acad. Sci., 87:1436, Focal Accumulation of an Apolipoprotein B-Based Synthetic Oligopeptide in the Healing Rabbit Arterial Wall.
Baule et al., 1988, Biochem. Biophys. Res. Comm., 154:1054, Multiple Chick Tropoelastin MRNAS.
Senior et al., 1984, Journal of Cell Biology, 98:870, Val-Gly-Val-Ala-Pro-Gly-, A Repeating Peptide in Elastin, is Chemotactic for Fibroblasts and Monocytes.
International Search Report, PCT/US91/03026, dated 20 Aug. 1991.
Urry et al., "pK Shift of Functional Group in Mechanochemical Coupling Due to Hydrophobic Effect: Evidence for an apolar-polar repulsion free energy in water", 1988, Bichem. and Biophys. Research Commun., 153(2):832-39.
Srinivasan, S.R., et al. Dynamics of Lipoprotein-Glycosaminoglycan Interactions in the Atherosclerotic Rabbit Aorta In Vivo, Biochimica et
Findeis Mark A.
Fischman Allan
Lees Ann M.
Lees Robert S.
Shih Ing-Lung
Harle Jennifer
New England Deaconess Hospital Corporation
Tsang Cecilia J.
LandOfFree
Synthetic peptides for arterial imaging does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic peptides for arterial imaging, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptides for arterial imaging will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-139377